|
Re: Will we see 5 point MACE reduction results in BETONMACE
|
8
|
Resverlogix Corp.
|
Jun 18, 2019 12:32PM
|
|
Just under 72 hours to go......
|
8
|
Resverlogix Corp.
|
Nov 13, 2019 11:07AM
|
|
Updated Van Leeuwenhoeck Institute Analyst Report and August Fact Sheet
|
8
|
Resverlogix Corp.
|
Aug 02, 2018 05:06PM
|
|
Re: Positives & negatives
|
8
|
Resverlogix Corp.
|
Sep 16, 2015 02:08PM
|
|
Re: A lesson on futility analyses from the CETP inhibitors
|
8
|
Resverlogix Corp.
|
May 11, 2017 10:19AM
|
|
Re: Why worry about the Third Eye loan?
|
8
|
Resverlogix Corp.
|
Aug 27, 2019 08:48PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 07:39AM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
8
|
Zenith Epigenetics
|
Mar 15, 2021 09:53PM
|
|
Endocrine News
|
8
|
Resverlogix Corp.
|
Jun 01, 2017 10:40PM
|
|
Updated Agenda for next weeks Discovery on Target meeting 9/22 and 9/23
|
8
|
Resverlogix Corp.
|
Sep 16, 2015 03:11PM
|
|
Apabetalone: Dialing down the Dimmer Switch.
|
8
|
Resverlogix Corp.
|
Apr 29, 2019 12:16PM
|
|
H1 2020 Potential Events
|
8
|
Resverlogix Corp.
|
Feb 21, 2020 10:42PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 09:32AM
|
|
Re: Sub-study Forest Plot
|
8
|
Resverlogix Corp.
|
Nov 16, 2019 03:02PM
|
|
Re: DM
|
8
|
Resverlogix Corp.
|
Jul 13, 2017 12:06PM
|
|
NLRP3 inhibitors and apabetalone
|
8
|
Resverlogix Corp.
|
Jul 26, 2019 01:10PM
|
|
Re: Cytokine storm hypothesis takes a hit with the latest IL-6 targeted therapies
|
8
|
Resverlogix Corp.
|
Apr 27, 2020 02:27PM
|
|
Re: Presentation
|
8
|
Resverlogix Corp.
|
Jun 19, 2017 11:09PM
|
|
Re: Anacetrapib Officially Bites the Dust
|
8
|
Resverlogix Corp.
|
Oct 26, 2017 03:08PM
|
|
Re: Opportunity Knocks
|
8
|
Resverlogix Corp.
|
Jul 19, 2019 10:48AM
|
